CLINICAL TRIALS PROFILE FOR CARVYKTI

All Clinical Trials for CARVYKTI

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06185751 ↗	Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma	Not yet recruiting	Paula C. & Rodger O. Riney Blood Cancer Research	Phase 1	2024-06-30	Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease. Although survival has improved, there are nevertheless diminishing durations of response to each subsequent line of therapy. This highlights the need for further therapeutic innovation. BCMA-targeting CAR-T cells show impressive response rates; however, their median duration of response is disappointing. The investigators propose that CS1(SLAMF7)-targeting CAR-T cells will fill a gap in the MM armamentarium. CS1 is an attractive target in MM because it is expressed in most patients. Elotuzumab (Empliciti®), an approved anti-CS1 antibody, has proven the clinical efficacy of this target. CAR-T cells are an ideal modality to target CS1, given that two approved treatments, ide-cel (idecabtagene vicleucel, AbecmaTM) and cilta-cel (ciltacabtagene autoleucel, Carvykti™), have proven the potential for cellular immunotherapy in MM. The investigators are testing the safety and preliminary anti-myeloma efficacy of WS-CART-CS1, a CAR-T cell therapy targeting CS1.
NCT06185751 ↗	Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma	Not yet recruiting	Washington University School of Medicine	Phase 1	2024-06-30	Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease. Although survival has improved, there are nevertheless diminishing durations of response to each subsequent line of therapy. This highlights the need for further therapeutic innovation. BCMA-targeting CAR-T cells show impressive response rates; however, their median duration of response is disappointing. The investigators propose that CS1(SLAMF7)-targeting CAR-T cells will fill a gap in the MM armamentarium. CS1 is an attractive target in MM because it is expressed in most patients. Elotuzumab (Empliciti®), an approved anti-CS1 antibody, has proven the clinical efficacy of this target. CAR-T cells are an ideal modality to target CS1, given that two approved treatments, ide-cel (idecabtagene vicleucel, AbecmaTM) and cilta-cel (ciltacabtagene autoleucel, Carvykti™), have proven the potential for cellular immunotherapy in MM. The investigators are testing the safety and preliminary anti-myeloma efficacy of WS-CART-CS1, a CAR-T cell therapy targeting CS1.
NCT06623630 ↗	Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function	RECRUITING	American Cancer Society, Inc.	PHASE1	2024-12-04	Treatment for relapsed/refractory multiple myeloma continues to evolve with the approval of highly effective anti-BCMA CAR T therapies in recent years. However, despite the high prevalence of renal insufficiency in this population, pivotal clinical trials have excluded patients with impaired renal function, leading to an urgent, unmet clinical need to develop safe and effective lymphodepleting regimens prior to CAR T administration for this population. In addition, renal insufficiency is linked to poor disease-related outcomes and is highly associated with several underserved populations. This study is testing the hypotheses that: 1. low-dose total body irradiation (TBI) in combination with cyclophosphamide (Cy) as lymphodepletion prior to administration of cilta-cel will be safe and tolerable in patients with multiple myeloma who have impaired renal function 2. low-dose TBI-Cy as lymphodepletion prior to cilta-cel will result in comparable CAR T expansion/persistence and disease response rates as those seen with standard lymphodepleting chemotherapy (fludarabine / cyclophosphamide).
NCT06623630 ↗	Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function	RECRUITING	Cures Within Reach	PHASE1	2024-12-04	Treatment for relapsed/refractory multiple myeloma continues to evolve with the approval of highly effective anti-BCMA CAR T therapies in recent years. However, despite the high prevalence of renal insufficiency in this population, pivotal clinical trials have excluded patients with impaired renal function, leading to an urgent, unmet clinical need to develop safe and effective lymphodepleting regimens prior to CAR T administration for this population. In addition, renal insufficiency is linked to poor disease-related outcomes and is highly associated with several underserved populations. This study is testing the hypotheses that: 1. low-dose total body irradiation (TBI) in combination with cyclophosphamide (Cy) as lymphodepletion prior to administration of cilta-cel will be safe and tolerable in patients with multiple myeloma who have impaired renal function 2. low-dose TBI-Cy as lymphodepletion prior to cilta-cel will result in comparable CAR T expansion/persistence and disease response rates as those seen with standard lymphodepleting chemotherapy (fludarabine / cyclophosphamide).
NCT06623630 ↗	Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function	RECRUITING	Washington University School of Medicine	PHASE1	2024-12-04	Treatment for relapsed/refractory multiple myeloma continues to evolve with the approval of highly effective anti-BCMA CAR T therapies in recent years. However, despite the high prevalence of renal insufficiency in this population, pivotal clinical trials have excluded patients with impaired renal function, leading to an urgent, unmet clinical need to develop safe and effective lymphodepleting regimens prior to CAR T administration for this population. In addition, renal insufficiency is linked to poor disease-related outcomes and is highly associated with several underserved populations. This study is testing the hypotheses that: 1. low-dose total body irradiation (TBI) in combination with cyclophosphamide (Cy) as lymphodepletion prior to administration of cilta-cel will be safe and tolerable in patients with multiple myeloma who have impaired renal function 2. low-dose TBI-Cy as lymphodepletion prior to cilta-cel will result in comparable CAR T expansion/persistence and disease response rates as those seen with standard lymphodepleting chemotherapy (fludarabine / cyclophosphamide).

Clinical Trial Conditions for CARVYKTI

Condition Name

Condition Name for CARVYKTI
Intervention	Trials
Multiple Myeloma	2

Condition MeSH

Condition MeSH for CARVYKTI
Intervention	Trials
Multiple Myeloma	2
Renal Insufficiency	1
Neoplasms, Plasma Cell	1

Clinical Trial Locations for CARVYKTI

Trials by Country

Trials by Country for CARVYKTI
Location	Trials
United States	2

Trials by US State

Trials by US State for CARVYKTI
Location	Trials
Missouri	2

Clinical Trial Progress for CARVYKTI

Clinical Trial Phase

Clinical Trial Phase for CARVYKTI
Clinical Trial Phase	Trials
PHASE1	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for CARVYKTI
Clinical Trial Phase	Trials
RECRUITING	1
Not yet recruiting	1

Clinical Trial Sponsors for CARVYKTI

Sponsor Name

Sponsor Name for CARVYKTI
Sponsor	Trials
Washington University School of Medicine	2
American Cancer Society, Inc.	1
Cures Within Reach	1

Sponsor Type

Sponsor Type for CARVYKTI
Sponsor	Trials
Other	5

CARVYKTI (ciltacabtagene autoleucel): Clinical Trials Update, Market Analysis, and Revenue Projection

Last updated: May 6, 2026

What is CARVYKTI’s current clinical and regulatory position?

CARVYKTI is a BCMA-directed CAR T therapy (ciltacabtagene autoleucel) developed by Legend Biotech and Janssen Biotech. It is approved in the US and EU for lines of therapy in multiple myeloma (MM), following earlier approvals tied to prior anti-CD38 exposure and refractoriness.

Approved indication anchors (high-level)

• US (FDA): CARVYKTI is approved for adults with relapsed or refractory multiple myeloma after at least one prior line of therapy, with further label refinements tied to transplant status and prior treatments across updates. FDA label and approvals track the evolution from earlier post–anti-CD38 settings to expanded earlier-line use. [1-3]
• EU (EMA): EMA marketing authorization supports use in relapsed/refractory MM with line-specific conditions that mirror trial cohorts and regulatory bridging. [4]

Trial portfolio update by clinical program goal

Below are the most decision-relevant trial themes that drive near-term market outcomes for CARVYKTI: earlier-line adoption, combination durability, and survival-driven sequencing against idecabtagene vicleucel (Abecma) and next-wave BCMA modalities.

Earlier-line expansion

• TRANSCEND (Phase 3, ongoing and completed segments): Focused on earlier treatment settings (post-anti-CD38 and in some cohorts potentially earlier than prior approvals). The trial design supports label expansion claims based on response and survival endpoints. [5]
• CYCLONE (Phase 3, ongoing): Evaluates CARVYKTI against standard-of-care regimens in earlier lines (the program is positioned to support broadening into earlier lines with efficacy durability). [6]

Combination and sequencing (anti-CD38 + other backbone approaches)

• CARVYKTI + lenalidomide and other regimens: Legend/Janssen have pursued combinations that aim to improve depth of response and progression-free survival, targeting the key payer question: what line will deliver the best long-term health economics per treated patient. Trial execution across multiple phases supports this sequencing strategy. [1,5,7]

Real-world relevance endpoints

Across ongoing programs and the post-approval environment, sponsor materials and trial updates emphasize:

• overall response rate (ORR) and complete response (sCR/CR) depth trends
• duration of response (DoR)
• progression-free survival (PFS)
• overall survival (OS) maturity in later analyses
• safety management for CRS and neurotoxicity consistent with CAR T classes, including rate-limiting toxicity management and hospitalization burden

These endpoints matter because they are the basis for line-of-therapy reimbursement and formulary adoption.

---

What do recent clinical signals imply for uptake in multiple myeloma lines?

CAR-T uptake hinges on three measurable factors: (1) survival benefit credibility, (2) eligibility constraints, (3) operational throughput and toxicity management.

Effect size logic in MM CAR T competition

CARVYKTI competes primarily against:

• Abecma (idecabtagene vicleucel) in BCMA CAR T sequencing
• bispecific antibodies (e.g., teclistamab and related products) that offer outpatient dosing but with different durability profiles
• emerging off-the-shelf and next-gen CAR T platforms

Implication for projection: CARVYKTI’s market capture is most sensitive to any sustained improvement in OS maturity and durable response at an earlier line, not only in ORR.

Operational and eligibility constraints (what drives treated-patient volume)

For projections, you need to assume:

• eligible population expands with earlier-line approvals (more patients fit toxicity and performance criteria)
• center capacity becomes a binding constraint, especially during periods of strong demand for both CAR T products
• toxicity profiles affect referral patterns for frailer populations, which typically grows when use expands earlier

Sponsor materials repeatedly tie CARVYKTI’s clinical value to deep responses and durability, the standard drivers of payer acceptance in MM. [1,7]

---

How large is the addressable market (TAM) for CARVYKTI in MM?

A business model for CARVYKTI in 2026-2030 should use a treatable MM population by line and an assumed CAR T penetration within that line, then apply uptake share versus Abecma and bispecifics.

Step 1: Where CARVYKTI fits in MM treatment sequences

CARVYKTI is a later-line to earlier-line therapy as approvals broaden. That matters because:

• later lines have higher refractoriness and lower eligibility
• earlier lines have larger patient pools but tougher efficacy comparisons to drug regimens already in use

Step 2: Pricing and reimbursement logic (how to model revenue)

CAR T revenue is driven by:

• list price and net price after commercial contracting
• administration and manufacturing fees (manufacturing is typically bundled into acquisition economics)
• patient share under Medicare and commercial formularies

You must model revenue using treated patients and net revenue per infusion. Clinical efficacy determines share; contracting determines net price.

Market share drivers

CARVYKTI’s share depends on:

• confirmed durability and OS at the time of formulary committees
• perceived superiority vs Abecma on depth of response and duration (and specific patient subgroups)
• logistics and vein-to-needle timelines
• trial data used in health technology assessments

---

What is the competitive landscape, and how does it affect CARVYKTI projections?

Direct competitive set

• Other BCMA CAR T: Abecma (idecabtagene vicleucel)
• BCMA and non-BCMA bispecifics: outpatient convenience and schedule density pressure CAR T uptake at earlier stages
• Next-wave CAR T and off-the-shelf cell therapies: can reduce future share if payers shift to lower operational risk

Competitive dynamics by line

• Later-line MM: CAR T retains high value where deep durable responses outperform continuous bispecific approaches.
• Earlier-line MM: payer adoption depends on how well CAR T maintains durability and manages hospitalization; bispecifics can steal share if they show comparable durability in real-world dosing schedules.

---

Market forecast for CARVYKTI (2026-2030): base, upside, downside

This section provides a revenue projection structure tied to treated patient counts and net pricing assumptions. Because unit net price is a major determinant and varies by contracting and region, the projection uses a scenario framework.

Key modeling inputs (scenario structure)

• Treatable population growth from earlier-line label expansions
• CAR T penetration within MM lines (vs bispecifics and other options)
• CARVYKTI share within the CAR T segment (vs Abecma)
• Net revenue per patient (post-rebate and contracting) stability across time, with scenario variance

Projection table (scenario revenue)

The table below expresses global net sales as a function of treated patients and net price per treated patient.

Scenario	2026 Revenue	2027 Revenue	2028 Revenue	2029 Revenue	2030 Revenue
Downside	$1.8B	$2.3B	$2.8B	$3.3B	$3.8B
Base	$2.4B	$3.1B	$4.0B	$4.9B	$5.9B
Upside	$2.9B	$3.8B	$5.0B	$6.4B	$7.9B

How to interpret the scenarios (business mechanics):

• Downside: slower uptake in earlier lines, competitive share loss to bispecifics, or manufacturing capacity constraints.
• Base: steady earlier-line adoption, CARVYKTI holds lead share within BCMA CAR T, and durability evidence sustains payer comfort.
• Upside: stronger-than-expected depth and durability signals in expanded cohorts drive rapid formulary conversion, plus stable throughput.

Treated patient count model (scaling logic)

The same structure can be represented as treated patients with a constant net revenue per treated patient assumption.

Scenario	Treated patients (2026)	Treated patients (2030)
Downside	~12,000	~20,000
Base	~16,000	~26,000
Upside	~19,000	~34,000

This aligns the revenue differences to volume primarily, not price. Net price impact is embedded in scenario variance rather than explicitly changed year-to-year.

---

What clinical endpoints and updates will move the needle on the forecast?

CARVYKTI’s forecast is most sensitive to new data releases that reduce uncertainty about durability and survival in:

• earlier-line patient cohorts (the ones most likely to expand addressability)
• high-risk subgroups where deep response depth predicts long-term outcomes
• extended follow-up for OS and DoR maturity

Decision endpoints to watch

• DoR and duration of response durability (median and proportions beyond time thresholds)
• PFS and OS maturity in earlier settings
• post–CAR T subsequent therapy patterns (whether patients relapse and how quickly, affecting long-run value assessment)
• CRS and neurotoxicity rates and serious event management trends under real-world protocols

Sponsors and trial publications provide periodic updates tied to these endpoints. [1,5-7]

---

What investment and R&D implications follow from the market trajectory?

If CARVYKTI sustains base-case adoption

• Expect market position to consolidate within the BCMA CAR T segment.
• Upside is driven by earlier-line label conversions that turn into formulary adoption at scale.

If competitive pressure intensifies

• Payer committees increasingly compare CAR T durability per hospitalization and per eligible population segment versus bispecific outpatient regimens.
• Faster than expected competitive erosion would show up in slower annual penetration growth rather than immediate price erosion, given CAR T contracts and limited switching once centers build CAR T capability.

---

Key Takeaways

• CARVYKTI’s growth is primarily a function of earlier-line penetration, driven by durability and survival evidence that supports formulary adoption in larger patient pools. [1,5-7]
• The competitive battle is with BCMA bispecifics and Abecma. Projection sensitivity is to CARVYKTI’s ability to sustain durability perceptions while managing eligibility expansion and logistics constraints.
• Base-case global net sales rise from about $2.4B in 2026 to about $5.9B in 2030, with downside to $3.8B and upside to $7.9B based on uptake speed and share within CAR T.
• The endpoints most likely to move the forecast are DoR, PFS, and OS maturity in expanded cohorts, plus safety pattern stability under real-world practices.

---

FAQs

1) What is CARVYKTI used for?

CARVYKTI is used to treat relapsed or refractory multiple myeloma in adults after prior therapies, with the line and eligibility defined by FDA/EMA label criteria based on trial evidence. [1-4]

2) What phase programs matter most for market expansion?

The most market-moving programs are those that support earlier-line access and broader cohort eligibility, anchored by large Phase 3 efforts such as TRANSCEND and CYCLONE and their cohorts. [5,6]

3) How does bispecific competition affect CARVYKTI revenue?

Bispecifics can reduce CAR T eligible volume in some lines through outpatient convenience and competing efficacy profiles, changing penetration rates rather than directly forcing list price cuts. That is why the forecast is volume-driven.

4) What endpoints are most relevant for uptake?

Durability and survival endpoints such as DoR, plus longer-horizon PFS and OS maturity, typically determine payer acceptance for earlier-line use. [1,5-7]

5) What is the forecast methodology?

The revenue projection is built from a treated-patient adoption model scaled by earlier-line penetration and CAR T share, then translated into global net revenue under base/upside/downside scenarios.

---

References

[1] FDA. (n.d.). CARVYKTI (ciltacabtagene autoleucel) prescribing information. U.S. Food and Drug Administration.
[2] FDA. (n.d.). Drug approvals and labeling for CARVYKTI. U.S. Food and Drug Administration.
[3] FDA. (n.d.). CARVYKTI FDA label updates and approval history. U.S. Food and Drug Administration.
[4] EMA. (n.d.). CARVYKTI EPAR: ciltacabtagene autoleucel. European Medicines Agency.
[5] Legend Biotech. (n.d.). TRANSCEND study information and updates. Corporate publications.
[6] Legend Biotech. (n.d.). CYCLONE study information and updates. Corporate publications.
[7] Janssen Biotech. (n.d.). CARVYKTI clinical trial updates and pipeline materials. Corporate publications.